Drug intelligence / Profile preview

Cancerlysin

Development stage: Preclinical
Lead developer: ImmuVia
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Cancerlysin is a first-in-class bispecific apoptosis trigger (BAT) developed by ImmuVia. It utilizes a proprietary mechanism designed to efficiently cluster death receptors on the surface of cancer cells, thereby significantly enhancing the induction of apoptosis (programmed cell death). Unlike traditional therapies, BATs are engineered to target tumor cells specifically, minimizing damage to healthy tissues. The lead candidate, Cancerlysin IMV-M, has demonstrated broad anti-tumor efficacy in mouse xenograft models and a favorable safety profile in non-human primates. As of late 2024, the program remains in preclinical development.

Other names: Cancerlysin IMV-M

Targets

TNFRSF10B (DR5)MUC16 (Mucin-16)

Beyond the preview

Go deeper on Cancerlysin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cancerlysin.

Explore the full profile